SMA Niv denied as not FDA-approved for this use by Humana?

Humana's specific coverage criteria for sma niv are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Denied This Claim — and Why It's Appealable

Humana may issue a "not FDA-approved" denial for non-invasive ventilation (NIV) in spinal muscular atrophy (SMA) when the specific device configuration, interface, or mode of delivery does not appear on the submitted claim with adequate clinical justification, or when the insurer incorrectly conflates the device's regulatory status with coverage policy. NIV itself is an established respiratory support modality with a long FDA-clearance history; the denial is almost always a documentation or coding gap rather than a true regulatory problem.

## Your Federal Appeal Rights

Under ACA §2719 and its implementing regulations, you have the right to a full internal appeal followed by an independent external review through an IRO (Independent Review Organization) that Humana cannot control. If your plan is governed by ERISA §503, you are entitled to a "full and fair review" of any adverse benefit determination. The external review request window is generally four months from the denial notice date — do not let that deadline pass. An expedited review (often resolved in 72 hours) is available when your physician certifies that waiting for the standard timeline would seriously jeopardize your health.

## Concrete Appeal Steps

1. Request the denial rationale in writing — Humana must provide the specific clinical or regulatory basis within a defined timeframe. Ask for the applicable coverage policy number and the full text. 2. File the Level 1 internal appeal within the window stated on your Explanation of Benefits (EOB). 3. Escalate to Level 2 if the Level 1 appeal is upheld, or request external review simultaneously if your state allows concurrent filing. 4. Request expedited review if respiratory compromise makes delay medically dangerous.

## Documentation to Gather

• Diagnosis confirmation: Genetic testing confirming SMA type; pulmonologist or neuromuscular specialist notes documenting respiratory insufficiency.
• Prior treatment history: Dates and outcomes of any respiratory interventions already tried (e.g., supplemental oxygen, cough assist, earlier ventilatory support settings).
• Clinical severity: Pulmonary function test results, sleep study data, arterial or capillary blood gas values, and any documented respiratory events — all from the medical record, described qualitatively as "meeting the prescribing physician's clinical threshold."
• Prescriber medical-necessity letter: A detailed letter from the treating pulmonologist or neurologist explaining why NIV is the appropriate intervention, referencing the FDA-cleared indication for the specific device and citing the applicable guideline organization (e.g., the AAN or ATS guideline on SMA respiratory management).
• Device FDA clearance documentation: Pull the device's 510(k) or PMA summary from the FDA database and attach it — this directly refutes a "not FDA-approved" rationale.

## Criteria-Mapping Structure

Create a two-column table. Left column: each requirement from (a) the device's FDA-cleared labeling and (b) Humana's published medical/coverage policy for home ventilator support. Right column: the exact chart fact that satisfies each requirement. This structure forces the reviewer to address every element individually and leaves no gap for a blanket denial to stand.

An attorney or certified patient advocate experienced in ERISA respiratory-device appeals can significantly improve outcomes if the internal process fails.